September 27, 2023 It has probably been quite a while since you’ve given much thought to retinoblastoma (RB). After all it is quite rare, and as optometrists we’re not likely to be much involved in
August 23, 2023 The retina world continues to make headlines as we move into the fourth quarter of 2023; not all of it has been good news. In February, we saw the U.S. Food and
July 26, 2023 The evolution of optometry into medical eye care began to take off in the early 1970s when Rhode Island became the first state to be granted diagnostic privileges, followed a few years
June 26, 2023 In the current era of modern technology, why are we still recommending an Amsler grid to our patients with macular degeneration? The Amsler grid dates back to 1947 and is named after
May 24, 2023 One of the most controversial topics surrounding the management of diabetic retinopathy revolves around when patients should be treated. Should we follow the traditional path of waiting until patients develop proliferative diabetic
April 24, 2023 There has been a lot of attention around age-related macular degeneration (AMD) over the past several months with the approval of pegcetacoplan for the treatment of geographic atrophy (GA) as well as
April 11, 2023 The buzz in the retina community is the potential of finally having a treatment for geographic atrophy (GA), the dry, atrophic form of macular degeneration. It is expected that by the first
April 11, 2023 One of the holy grails in eye care has been finding a cure for presbyopia that doesn’t involve spectacle lenses or contact lenses. Near the end of 2021, Allergan came the closest
April 11, 2023 The introduction of the anti-VEGF drugs beginning in 2006 for the treatment of neovascular AMD (nAMD), followed a few years later with their approval for diabetic macular edema (DME), revolutionized the management
